{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:37Z","timestamp":1786986937559,"version":"build-2736575974"},"reference-count":168,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.017","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:30:17Z","timestamp":1659493817000},"page":"e1019-e1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment Landscape of Relapsed\/Refractory Mantle Cell Lymphoma: An Updated Review"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-4924","authenticated-orcid":false,"given":"Mubarak","family":"Al-Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.017_bib0001","doi-asserted-by":"crossref","first-page":"112516","DOI":"10.18632\/oncotarget.22367","article-title":"Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.07.017_bib0002","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1182\/blood-2019-129677","article-title":"A systematic review of the epidemiology and economic burden of Mantle Cell Lymphoma (MCL)","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0003","first-page":"1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J Hematol and Oncol. BioMed Central Ltd."},{"key":"10.1016\/j.clml.2022.07.017_bib0004","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-49326-3","article-title":"Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy. Sci Rep","volume":"9","author":"Kolodziej","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.clml.2022.07.017_bib0006","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase III non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.07.017_bib0007","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0008","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol [Internet]. J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2014.03.006","article-title":"Clinical efficacy and safety in relapsed\/refractory mantle cell lymphoma: A systematic literature review","volume":"15","author":"Njue","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.07.017_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2017.10.004","article-title":"A systematic review of treatments of relapsed\/refractory mantle cell lymphoma","volume":"18","author":"Parrott","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 4","key":"10.1016\/j.clml.2022.07.017_bib0011","first-page":"50S","article-title":"Mantle Cell Lymphoma: An Evolving Therapeutic Landscape","volume":"32","author":"Roschewski","year":"2015","journal-title":"Fed Pract Frontline Med Comm"},{"key":"10.1016\/j.clml.2022.07.017_bib0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A mutated B-cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0013","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2011-03-341651","article-title":"Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity","volume":"118","author":"Warsame","year":"2011","journal-title":"Blood. U S"},{"key":"10.1016\/j.clml.2022.07.017_bib0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V96.1.9","article-title":"Fates human B-cell precursors","volume":"96","author":"LeBien","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0016","first-page":"1073","article-title":"In vivo ablation of surface immunoglobulin on mature B-cells by inducible gene targeting results in rapid cell death","volume":"90","author":"Lam","year":"1997","journal-title":"Cell. U S"},{"key":"10.1016\/j.clml.2022.07.017_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-811X-10-21","article-title":"Functions of the Lyn tyrosine kinase in health and disease","volume":"10","author":"Ingley","year":"2012","journal-title":"Cell Commun and Sign"},{"key":"10.1016\/j.clml.2022.07.017_bib0018","doi-asserted-by":"crossref","first-page":"32662","DOI":"10.1074\/jbc.274.46.32662","article-title":"SYK is upstream of phosphoinositide 3-kinase in B-cell receptor signaling","volume":"274","author":"Beitz","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2022.07.017_bib0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood.V128.22.303.303","article-title":"Inhibition disrupts the cross-talk between B-Cell Activation Factor (BAFF) and B-Cell Receptor (BCR) and thereby antagonizes Mcl-1 in Chronic Lymphocytic Leukemia (CLL) B-Cells","volume":"128","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0020","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0021","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/0952-7915(95)80006-9","article-title":"Positive and negative selection events during B lymphopoiesis","volume":"7","author":"Melchers","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clml.2022.07.017_bib0022","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.4049\/jimmunol.1102479","article-title":"Negative selection by IgM superantigen defines a B-cell central tolerance compartment and reveals mutations allowing escape","volume":"187","author":"Duong","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2022.07.017_bib0023","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1136\/ard.2008.098459","article-title":"The PI3K\/Akt\/mTOR pathway in innate immune cells: Emerging therapeutic applications","volume":"67","author":"Weichhart","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.clml.2022.07.017_bib0024","doi-asserted-by":"crossref","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","article-title":"Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma","volume":"111","author":"Perry","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2022.07.017_bib0025","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood.V120.21.1492.1492","article-title":"Therapeutic utility of PI3K\u03b3 inhibition in leukemogenesis and tumor cell survival","volume":"120","author":"Diacovo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol. England"},{"key":"10.1016\/j.clml.2022.07.017_bib0027","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clml.2022.07.017_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase C\u03b32 mediate chemokine-controlled B-cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2022.07.017_bib0029","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-Cell non-hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.07.017_bib0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2019-127509","article-title":"Results from a first-in-human, proof-of-concept phase I trial in pretreated B-Cell malignancies for loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.07.017_bib0031","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase I, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-Cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0032","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","article-title":"Safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase II trial","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0033","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.07.017_bib0034","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0036","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase III study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.07.017_bib0037","article-title":"Ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: real life data from the \u201cRete Ematologica Del Lazio Per I Linfomi\u201d (Relli)","volume":"39","author":"Mariani","year":"2021"},{"key":"10.1016\/j.clml.2022.07.017_bib0038","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0039","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase III, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.017_bib0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.14122","article-title":"Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement \u2013 a multi-centre case series from the United Kingdom","volume":"178","author":"Tucker","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0041","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V128.22.2985.2985","article-title":"Multicenter retrospective observational study to assess the clinical characteristics and the outcome of patients with relapsed or refractory mantle cell non-hodgkin's lymphoma treated in italy according to the ibrutinib named patient program","volume":"128","author":"Stefoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0042","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2022.07.017_bib0043","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma\u2014a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0044","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Hematologica [Internet]. Hematologica;"},{"key":"10.1016\/j.clml.2022.07.017_bib0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.54_2630","article-title":"Ibrutinib compared to standard chemotherapy for central nervous system recurrence of mantle cell lymphoma","volume":"37","author":"Rusconi","year":"2019","journal-title":"Hematol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.017_bib0046","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1200\/JCO.2021.39.15_suppl.e19527","article-title":"Outcomes in mantle cell lymphoma with central nervous system involvement","volume":"39","author":"McLaughlin","year":"2021","journal-title":"J Clin Oncol. Wolters Kluwer Health;"},{"key":"10.1016\/j.clml.2022.07.017_bib0047","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1080\/10428194.2018.1457148","article-title":"Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials","volume":"59","author":"Agarwal","year":"2018","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.clml.2022.07.017_bib0048","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0049","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood.V124.21.4461.4461","article-title":"Safety results from the United States cohort of the ibrutinib early access treatment protocol (EAP: MCL4001) in patients with relapsed or refractory mantle cell lymphoma","volume":"124","author":"Martin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.119.262063","article-title":"Relative selectivity of covalent inhibitors requires assessment of inactivation kinetics and cellular occupancy: a case study of ibrutinib and acalabrutinib","volume":"372","author":"Hopper","year":"2020","journal-title":"J Pharmacol Exp Ther. NLM (Medline)"},{"key":"10.1016\/j.clml.2022.07.017_bib0051","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase I clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0052","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-134824","article-title":"Acalabrutinib Monotherapy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase II Study","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0053","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/refractory B-Cell malignancies: initial report of a phase I first-in-human trial","volume":"126","author":"Tam","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0054","first-page":"1","article-title":"Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials","volume":"14","author":"Zhou","year":"2021","journal-title":"J Hematol Oncol [Internet]. BioMed Central Ltd;"},{"key":"10.1016\/j.clml.2022.07.017_bib0055","first-page":"3365","article-title":"VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma","volume":"24","author":"Wang","year":"2020","journal-title":"Blood. ASH;"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0056","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1182\/blood-2021-145920","article-title":"BRUIN MCL-321: a phase III open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor na\u00efve mantle cell lymphoma (Trial in Progress)","volume":"138","author":"Eyre","year":"2021","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.clml.2022.07.017_bib0057","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0058","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase I study of the PI3Kd inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0059","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/bloodadvances.2020001685","article-title":"Targeting phosphatidylinositol 3 kinase-b and -d for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.017_bib0060","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase-I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0061","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase-II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0062","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood.V128.22.3016.3016","article-title":"The effects of PI3K-\u03b4\/\u03b3 inhibitor, duvelisib, in mantle cell lymphoma in vitro and in patient-derived xenograft studies","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0063","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.V128.22.1837.1837","article-title":"Pre-clinical evaluation of the PI3K-p110\u03b2\/\u03b4 inhibitor KA2237 in mantle cell lymphoma","volume":"128","author":"Huang","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0064","first-page":"38","article-title":"Results from a Phase I dose escalation study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in Chinese patients with relapsed\/refractory (R\/R) lymphomas","volume":"136","author":"Cao","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-134872","article-title":"Phase II study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor (CITADEL-205)","volume":"136","author":"Mehta","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0066","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-134872","article-title":"Phase II study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor (CITADEL-205)","volume":"136","author":"Mehta","year":"2020","journal-title":"Blood. ASH;"},{"key":"10.1016\/j.clml.2022.07.017_bib0067","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0068","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semi in Oncol. W.B. Saunders;"},{"key":"10.1016\/j.clml.2022.07.017_bib0069","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/toxics3030294","article-title":"An overview of bortezomib-induced neurotoxicity","volume":"3","author":"Meregalli","year":"2015","journal-title":"Toxics"},{"key":"10.1016\/j.clml.2022.07.017_bib0070","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15107","article-title":"A phase-II study of carfilzomib in the treatment of relapsed\/refractory mantle cell lymphoma","volume":"184","author":"Lee","year":"2019","journal-title":"British J Hematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0071","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","article-title":"Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis","volume":"59","author":"Shah","year":"2018","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.clml.2022.07.017_bib0072","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/aol.2019.01.01","article-title":"Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?","volume":"3","author":"Albertsson-Lindblad","year":"2019","journal-title":"Ann Lymphoma"},{"key":"10.1016\/j.clml.2022.07.017_bib0073","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood.V128.22.1798.1798","article-title":"MAGNIFY: Phase-IIIb randomized study of lenalidomide plus rituximab (R2) followed by lenalidomide vs. rituximab maintenance in subjects with relapsed\/refractory follicular, marginal zone, or mantle cell lymphoma","volume":"128","author":"Andorsky","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0074","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase-II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase II, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0076","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0077","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.clml.2022.07.017_bib0078","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"MTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell and Bioscience. BioMed Central Ltd."},{"key":"10.1016\/j.clml.2022.07.017_bib0079","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase-III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase II study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0081","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-015-2570-1","article-title":"Temsirolimus acts as additive with bendamustine in aggressive lymphoma","volume":"95","author":"Zoellner","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0082","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V128.22.2977.2977","article-title":"Temsirolimus in combination with bendamustine and rituximab (BeRT) for the treatment of relapsed mantle cell and follicular lymphoma: final Phase-I\/II results","volume":"128","author":"Hess","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol.2019.12.01","article-title":"Targeting CDK4\/6 in mantle cell lymphoma","volume":"4","author":"Lee","year":"2020","journal-title":"Ann Lymphoma"},{"key":"10.1016\/j.clml.2022.07.017_bib0084","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0085","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3Kd inhibition through PIK3IP1","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle. Taylor and Francis Inc."},{"key":"10.1016\/j.clml.2022.07.017_bib0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212574","article-title":"Evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context. Bioexcel Publishing LTD;"},{"key":"10.1016\/j.clml.2022.07.017_bib0087","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase-I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"8","author":"Davids","year":"2017","journal-title":"J Clin Oncols"},{"key":"10.1016\/j.clml.2022.07.017_bib0088","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-138878","article-title":"Outcomes of patients with relapsed mantle cell lymphoma treated with venetoclax: a multicenter retrospective analysis","volume":"136","author":"Sawalha","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0089","doi-asserted-by":"crossref","first-page":"e01297","DOI":"10.1016\/j.heliyon.2019.e01297","article-title":"Therapeutic antibodies for mantle cell lymphoma: a brand-new era ahead","volume":"5","author":"Sun","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.clml.2022.07.017_bib0090","first-page":"317","article-title":"European phase-II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol. Lippincott Williams and Wilkins;"},{"key":"10.1016\/j.clml.2022.07.017_bib0091","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0092","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.clml.2022.07.017_bib0093","first-page":"93","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J Hematol and Oncol. BioMed Central"},{"key":"10.1016\/j.clml.2022.07.017_bib0094","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A phase-I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody\u2013drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin Cancer Res Am Assoc for Cancer Research Inc."},{"key":"10.1016\/j.clml.2022.07.017_bib0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science (80-)"},{"key":"10.1016\/j.clml.2022.07.017_bib0096","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jamcollsurg.2004.01.025","article-title":"Development of effective immunotherapy for the treatment of patients with cancer","volume":"198","author":"Rosenberg","year":"2004","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clml.2022.07.017_bib0097","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2796.2001.00911.x","article-title":"Progress in the development of immunotherapy for the treatment of patients with cancer","volume":"250","author":"Rosenberg","year":"2001","journal-title":"J Intern Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0098","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1242\/dmm.018036","article-title":"Genetically modified T cells in cancer therapy: opportunities and challenges","volume":"8","author":"Sharpe","year":"2015","journal-title":"DMM Dis Model Mech"},{"key":"10.1016\/j.clml.2022.07.017_bib0099","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T Cells: a race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfusion Med and Hemotherapy"},{"key":"10.1016\/j.clml.2022.07.017_bib0100","first-page":"375","article-title":"The use of chimeric antigen receptor T cells in patients with non-hodgkin lymphoma","volume":"16","author":"Lulla","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0101","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2022.07.017_bib0102","first-page":"20","article-title":"One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood. ASH;"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.017_bib0103","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1200\/JCO.2021.39.15_suppl.7547","article-title":"Outcomes with KTE-X19 in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol. Wolters Kluwer Health;"},{"key":"10.1016\/j.clml.2022.07.017_bib0104","article-title":"KTE-X19 versus standard of care for relapsed\/refractory mantle cell lymphoma previously treated with bruton tyrosine kinase inhibitors: real-world evidence from Europe","author":"Hess","year":"2021","journal-title":"Euro Hematol Ass [Internet]"},{"issue":"1","key":"10.1016\/j.clml.2022.07.017_bib0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood. ASH;"},{"key":"10.1016\/j.clml.2022.07.017_bib0106","article-title":"Early safety and efficacy findings of auto1 (CAT19), a fast-off rate CD19 car, in relapsed \/refractory indolent B-cell lymphomas","author":"Roddie","year":"2021","journal-title":"Euro Hematol Assoc [Internet]"},{"key":"10.1016\/j.clml.2022.07.017_bib0107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clml.2022.07.017_bib0108","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"A CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.017_bib0109","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of Patients with relapsed\/refractory non-Hodgkin lymphoma: Final results from a Phase-I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0110","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.07.017_bib0111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-Cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.07.017_bib0112","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical activity of REGN1979, a bispecific human, Anti-CD20 x Anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.07.017_bib0113","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2019-123949","article-title":"Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-Cell non-hodgkin lymphoma: preliminary results from a Phase-Ib trial","volume":"134","author":"Morschhauser","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.017_bib0114","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2021.39.15_suppl.7518","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity","volume":"39","author":"Clausen","year":"2021","journal-title":"J Clin Oncol. Wolters Kluwer Health;"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2021-148949","article-title":"Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R\/R) mantle cell lymphoma (MCL), most of whom had failed prior bruton's tyrosine kinase inhibitor (BTKi) therapy","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood [Internet]"},{"issue":"S2","key":"10.1016\/j.clml.2022.07.017_bib0116","article-title":"Phase-I study of the Cd19\/Cd3 half-life extended bite \u00ae molecule Amg 562 in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma","volume":"39","author":"Mead","year":"2021","journal-title":"Hematol Oncol [Internet]"},{"key":"10.1016\/j.clml.2022.07.017_bib0117","first-page":"1","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol [Internet]. BioMed Central;"},{"key":"10.1016\/j.clml.2022.07.017_bib0118","series-title":"Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies","first-page":"181","author":"Cooper","year":"2019"},{"key":"10.1016\/j.clml.2022.07.017_bib0119","first-page":"858","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol [Internet]. Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0120","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase II study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"G\u00f6kbuget","year":"2017","journal-title":"Hematologica [Internet]"},{"key":"10.1016\/j.clml.2022.07.017_bib0121","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment [Internet]","volume":"7","author":"Mejstr\u00edkov\u00e1","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.07.017_bib0122","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","article-title":"Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0123","first-page":"2578","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood [Internet]. Blood;"},{"key":"10.1016\/j.clml.2022.07.017_bib0124","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0125","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.07.017_bib0126","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0127","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1182\/blood.V124.21.4453.4453","article-title":"Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase II study","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase II trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0129","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between ibrutinib and anti-CD20 antibodies: Competing effects on the outcome of combination therapy","volume":"22","author":"Skarzynski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.07.017_bib0130","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0131","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","article-title":"Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas","volume":"21","author":"Chong","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0132","first-page":"36","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: final results from the nordic lymphoma group MCL6 (PHILEMON) phase-II trial","volume":"136","author":"Jerkeman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0133","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: Synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0134","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.07.017_bib0135","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2019-126619","article-title":"Three Year Update of the Phase-II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0136","first-page":"179","article-title":"Ibrutinib plus venetoclax in patients with relapsed\/refractory mantle cell lymphoma: results from the safety run-in period of the Phase 3 sympatico study","volume":"14","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0137","article-title":"Phase-I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma","volume":"39","author":"Kumar","year":"2021"},{"key":"10.1016\/j.clml.2022.07.017_bib0138","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2022.07.017_bib0139","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-140871","article-title":"Oncogenic MALT1 promotes cell survival and mediates ibrutinib resistance and ibrutinib-venetoclax resistance in mantle cell lymphoma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase III trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0141","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0142","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2018-99-113777","article-title":"Ibrutinib plus obinutuzumab and venetoclax in relapsed\/refractory mantle cells lymphoma patients, results of the OASIS Phase-I clinical trial","volume":"132","author":"Le Gouill","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.017_bib0143","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2020.38.15_suppl.8036","article-title":"Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase-Ib\/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)","volume":"38","author":"Lee","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.017_bib0144","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1200\/JCO.2021.39.15_suppl.7556","article-title":"Phase I\/II study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)","volume":"39","author":"Lee","year":"2021","journal-title":"J Clin Oncol. Wolters Kluwer Health;"},{"key":"10.1016\/j.clml.2022.07.017_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12061565","article-title":"Management of drug resistance in mantle cell lymphoma","volume":"12","author":"Rou\u00e9","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2022.07.017_bib0146","first-page":"207","article-title":"Sakk 36\/13-ibrutinib and bortezomib followed by ibrutinib maintenance in patients with relapsed and refractory mantle cell lymphoma: Phase-I report of a Phase-I\/II trial","volume":"35","author":"Novak","year":"2017"},{"key":"10.1016\/j.clml.2022.07.017_bib0147","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A Phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.017_bib0148","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1200\/JCO.2021.39.15_suppl.7553","article-title":"Initial results of the combination of PI3K\u03b4 inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R\/R) B-cell malignancies","volume":"39","author":"Soumerai","year":"2021","journal-title":"J Clin Oncol. Wolters Kluwer Health;"},{"key":"10.1016\/j.clml.2022.07.017_bib0149","series-title":"Interim Results of Loncastuximab Tesirine Combined with Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)","author":"Depaus","year":"2020"},{"key":"10.1016\/j.clml.2022.07.017_bib0150","doi-asserted-by":"crossref","DOI":"10.1002\/hon.150_2880","article-title":"Clinical activity of loncastuximab tesirine plus ibrutinib in non-hodgkin lymphoma: updated lotis 3 Phase I results","volume":"39","author":"Depaus","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0151","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A Phase I\/II clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"S2","key":"10.1016\/j.clml.2022.07.017_bib0152","article-title":"Induction R 2 followed by maintenance in patients with relapsed\/refractory mantle cell lymphoma: interim analysis from the Phase 3B magnify study","volume":"39","author":"Sharman","year":"2021","journal-title":"Hematol Oncol [Internet]"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.07.017_bib0153","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-133273","article-title":"Venetoclax, lenalidomide and rituximab for patients with relapsed or refractory mantle cell lymphoma - data from the nordic lymphoma group NLG-MCL7 (VALERIA) Phase-I trial: stopping treatment in molecular remission is feasible","volume":"136","author":"Jerkeman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.017_bib0154","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase II study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0155","first-page":"684","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020"},{"key":"10.1016\/j.clml.2022.07.017_bib0156","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.017_bib0157","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0158","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol. England"},{"key":"10.1016\/j.clml.2022.07.017_bib0159","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12185-016-2164-2","article-title":"Current treatment strategies in relapsed\/refractory mantle cell lymphoma: where are we now?","volume":"105","author":"Atilla","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2022.07.017_bib0160","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.07.017_bib0161","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.15723","article-title":"Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma","volume":"184","author":"Rule","year":"2019","journal-title":"Br J Hematol England"},{"key":"10.1016\/j.clml.2022.07.017_bib0162","first-page":"1","article-title":"Weekly Operational Update on COVID-19","year":"2021","journal-title":"World Heal Organ [Internet]"},{"key":"10.1016\/j.clml.2022.07.017_bib0163","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clml.2022.07.017_bib0164","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.annonc.2020.04.006","article-title":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City","volume":"31","author":"Miyashita","year":"2020","journal-title":"Ann of Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garci\u00e1-Su\u00e1rez","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.017_bib0166","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s41409-020-0931-4","article-title":"COVID-19 outcomes in patients with hematologic disease","volume":"55","author":"Malard","year":"2020","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.clml.2022.07.017_bib0167","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.017_bib0168","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2019.02.004","article-title":"Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient","volume":"33","author":"Fontana","year":"2019","journal-title":"Infectious Dis Clin of North Am"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:36Z","timestamp":1761871296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":168,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002373"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Landscape of Relapsed\/Refractory Mantle Cell Lymphoma: An Updated Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}